Year |
Citation |
Score |
2023 |
Kincer LP, Schnell G, Swanstrom R, Miller MB, Spudich S, Eron JJ, Price RW, Joseph SB. HIV-1 is Transported into the Central Nervous System by Trafficking Infected Cells. Pathogens & Immunity. 7: 131-142. PMID 36865569 DOI: 10.20411/pai.v7i2.524 |
0.697 |
|
2020 |
Yao BB, Fredrick LM, Schnell G, Kowdley KV, Kwo PY, Poordad F, Nguyen K, Lee SS, George C, Wong F, Gane E, Abergel A, Spearman CW, Nguyen T, Le MH, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5/6: An Integrated Analysis of Phase 2/3 Studies. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 32445613 DOI: 10.1111/Liv.14535 |
0.364 |
|
2019 |
Fuchs M, Monto A, Bräu N, Charafeddine M, Schmidt W, Kozal M, Naggie S, Cheung R, Schnell G, Yu Y, Richards K, Mullally V, Cohen DE, Toro D. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for Chronic HCV Infection in US Veterans with Psychiatric Disorders. Journal of Medical Virology. PMID 31829433 DOI: 10.1002/Jmv.25655 |
0.381 |
|
2019 |
Lawitz E, Flisiak R, Abunimeh M, Sise ME, Park JY, Kaskas M, Bruchfeld A, Wörns MA, Aglitti A, Zamor PJ, Xue Z, Schnell G, Jalundhwala YJ, Porcalla A, Mensa FJ, et al. Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Patients with Chronic HCV Infection. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 31821716 DOI: 10.1111/Liv.14320 |
0.346 |
|
2019 |
Brown RS, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horváth G, Zuckerman E, Carrion BR, Rodriguez-Perez F, Urbánek P, Abergel A, Cohen E, Lovell SS, Schnell G, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial. Journal of Hepatology. PMID 31682879 DOI: 10.1016/J.Jhep.2019.10.020 |
0.328 |
|
2019 |
Yao BB, Asselah T, Frederick L, Schnell G, Kowdley K, Kwo PY, Poordad F, Nguyen K, Lee SS. IDDF2019-ABS-0211 Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: an integrated analysis of phase 2 and 3 studies Gut. 68. DOI: 10.1136/Gutjnl-2019-Iddfabstracts.285 |
0.365 |
|
2019 |
Brown RS, Hezode C, Wang S, Buti M, Chuang W, Aguilar H, Horvath G, Carrion BR, Rodriguez-Perez F, Cohen E, Hu YB, Schnell G, Lin C, Rodrigues L, Trinh R, et al. IDDF2019-ABS-0210 Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1–6 infection and compensated cirrhosis: the EXPEDITION-8 study Gut. 68. DOI: 10.1136/Gutjnl-2019-Iddfabstracts.284 |
0.35 |
|
2019 |
Yao B, Asselah T, Fredrick L, Schnell G, Kowdley KV, Kwo P, Poordad F, Nguyen K, Lee S, Mensa F. THU-194-Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies Journal of Hepatology. 70. DOI: 10.1016/S0618-8278(19)30469-4 |
0.346 |
|
2018 |
Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Wyles DL, Schnell G, Alami NN, Zhang Z, Dumas E, Dore GJ. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. Open Forum Infectious Diseases. 5: ofy248. PMID 30430131 DOI: 10.1093/Ofid/Ofy248 |
0.382 |
|
2018 |
Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. The Lancet. Gastroenterology & Hepatology. PMID 30393106 DOI: 10.1016/S2468-1253(18)30341-8 |
0.406 |
|
2018 |
Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng TI, Xie W, Pilot-Matias T, Collins C. Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. Plos One. 13: e0205186. PMID 30286205 DOI: 10.1371/Journal.Pone.0205186 |
0.359 |
|
2018 |
Ng TI, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, Beyer J, Dekhtyar T, Irvin M, Lu L, Asatryan A, Campbell A, Yao B, Lovell S, Mensa F, et al. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses. 10. PMID 30154359 DOI: 10.3390/V10090462 |
0.408 |
|
2018 |
Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled Resistance Analysis in HCV Genotype 1-6 Infected Patients Treated With Glecaprevir/Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrobial Agents and Chemotherapy. PMID 30061289 DOI: 10.1128/Aac.01249-18 |
0.387 |
|
2018 |
Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Dekhtyar T, Irvin M, Hall C, Yu Y, Mobashery N, Redman R, Pilot-Matias T, Collins C. Characterization of Demographics and NS5A Genetic Diversity for HCV Genotype 4-Infected Patients with or without Cirrhosis Treated with Ombitasvir/Paritaprevir/Ritonavir. Journal of Viral Hepatitis. PMID 29624809 DOI: 10.1111/Jvh.12906 |
0.409 |
|
2018 |
Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Lu L, Ng IC, Xie W, Pilot-Matias T, Collins C. HCV genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with Glecaprevir and Pibrentasvir Journal of Hepatology. 68. DOI: 10.1016/S0168-8278(18)30768-2 |
0.324 |
|
2017 |
Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M, Redman R, Kumada H, Chayama K, Collins C, Pilot-Matias T. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in HCV Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrobial Agents and Chemotherapy. PMID 29180522 DOI: 10.1128/Aac.02217-17 |
0.427 |
|
2017 |
Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrobial Agents and Chemotherapy. PMID 29084747 DOI: 10.1128/Aac.01620-17 |
0.325 |
|
2017 |
Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues-Jr L, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, et al. Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir. Journal of Medical Virology. PMID 28842997 DOI: 10.1002/Jmv.24923 |
0.419 |
|
2017 |
Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrobial Agents and Chemotherapy. PMID 28193664 DOI: 10.1128/Aac.02558-16 |
0.331 |
|
2017 |
Pilot-Matias T, Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Irvin M, Dekhtyar T, Ng T, Lei Y, Asatryan A, Mensa F, Collins C. Resistance analysis in the MAGELLAN-1 Study (Part 2): glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors Journal of Hepatology. 66. DOI: 10.1016/S0168-8278(17)31898-6 |
0.363 |
|
2017 |
Krishnan P, Schnell G, Tripathi R, Ng T, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa F, Pilot-Matias T, Collins C. Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials Journal of Hepatology. 66. DOI: 10.1016/S0168-8278(17)31399-5 |
0.353 |
|
2017 |
Ng T, Lu L, Reisch T, Krishnan P, Schnell G, Tripathi R, Beyer J, Dekhtyar T, Irvin M, Pilot-Matias T, Collins C. Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes Journal of Hepatology. 66. DOI: 10.1016/S0168-8278(17)30972-8 |
0.359 |
|
2016 |
Sarrazin C, Sulkowski MS, Krishnan P, Tripathi R, Schnell G, Xie Y, Cohen DE, Trinh R, Rodrigues L, Luo Y, Shulman NS, Pilot-Matias T, Collins C. Effect of Baseline Resistance-Associated Variants on SVR with the 3D Regimen with and without RBV in GT1a and GT1b-Infected Patients: 854 The American Journal of Gastroenterology. 111. DOI: 10.14309/00000434-201610001-00854 |
0.357 |
|
2016 |
Ng T, Pilot-Matias T, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, Wang S, Mensa F, Kort J, Collins C. Analysis of Hepatitis C Virus (HCV) Genotype 2 and 3 Variants in Patients Treated With Combination Therapy of Next-Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530 Open Forum Infectious Diseases. 3. DOI: 10.1093/Ofid/Ofw172.294 |
0.35 |
|
2016 |
Ng T, Pilot-Matias T, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, Wang S, Mensa F, Kort J, Collins C. Analysis of HCV Genotype 2 and 3 Variants in Patients Treated with Combination Therapy of Next Generation HCV Direct-Acting Antiviral Agents ABT-493 and ABT-530 Journal of Hepatology. 64. DOI: 10.1016/S0168-8278(16)00653-X |
0.314 |
|
2016 |
Sarrazin C, Sulkowski MS, Krishnan P, Tripathi R, Schnell G, Xie Y, Cohen DE, Trinh R, Rodrigues L, Luo Y, Shulman NS, Pilot-Matias T, Collins C. Effect of Baseline Resistance-Associated Variants on SVR with the 3D Regimen with and without RBV in GT1A and GT1B-Infected Patients Journal of Hepatology. 64. DOI: 10.1016/S0168-8278(16)00180-X |
0.357 |
|
2015 |
Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X, Setze C, Rodrigues L, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Analysis of HCV Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir/Ritonavir and Ombitasvir. Antimicrobial Agents and Chemotherapy. PMID 26643326 DOI: 10.1128/Aac.02606-15 |
0.397 |
|
2015 |
Arrildt KT, LaBranche CC, Joseph SB, Dukhovlinova EN, Graham WD, Ping LH, Schnell G, Sturdevant CB, Kincer LP, Mallewa M, Heyderman RS, Van Rie A, Cohen MS, Spudich S, Price RW, et al. Phenotypic Correlates of HIV-1 Macrophage Tropism. Journal of Virology. PMID 26339058 DOI: 10.1128/Jvi.00946-15 |
0.73 |
|
2015 |
Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, Dekhtyar T, Hall C, Vilchez RA, Pilot-Matias T, Collins C. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. Antimicrobial Agents and Chemotherapy. PMID 26282418 DOI: 10.1128/Aac.01229-15 |
0.405 |
|
2015 |
Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T, Pilot-Matias T, Collins C. Resistance Analysis of Baseline and Treatment-Emergent Variants in the AVIATOR Study With Paritaprevir/r, Ombitasvir and Dasabuvir in HCV Genotype 1. Antimicrobial Agents and Chemotherapy. PMID 26100711 DOI: 10.1128/Aac.00998-15 |
0.39 |
|
2015 |
Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet (London, England). 385: 2502-9. PMID 25837829 DOI: 10.1016/S0140-6736(15)60159-3 |
0.377 |
|
2015 |
Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalized replication of R5 T cell-tropic HIV-1 in the central nervous system early in the course of infection. Plos Pathogens. 11: e1004720. PMID 25811757 DOI: 10.1371/Journal.Ppat.1004720 |
0.755 |
|
2015 |
Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, ... ... Schnell G, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Jama. 313: 1223-31. PMID 25706092 DOI: 10.1001/Jama.2015.1328 |
0.529 |
|
2014 |
Joseph SB, Arrildt KT, Swanstrom AE, Schnell G, Lee B, Hoxie JA, Swanstrom R. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. Journal of Virology. 88: 1858-69. PMID 24307580 DOI: 10.1128/Jvi.02477-13 |
0.708 |
|
2013 |
Stone AE, Giugliano S, Schnell G, Cheng L, Leahy KF, Golden-Mason L, Gale M, Rosen HR. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. Plos Pathogens. 9: e1003316. PMID 23637605 DOI: 10.1371/Journal.Ppat.1003316 |
0.367 |
|
2012 |
Sturdevant CB, Dow A, Jabara CB, Joseph SB, Schnell G, Takamune N, Mallewa M, Heyderman RS, Van Rie A, Swanstrom R. Central nervous system compartmentalization of HIV-1 subtype C variants early and late in infection in young children. Plos Pathogens. 8: e1003094. PMID 23300446 DOI: 10.1371/Journal.Ppat.1003094 |
0.752 |
|
2012 |
Schnell G, Loo YM, Marcotrigiano J, Gale M. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. Plos Pathogens. 8: e1002839. PMID 22912574 DOI: 10.1371/Journal.Ppat.1002839 |
0.327 |
|
2011 |
Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. HIV-1 replication in the central nervous system occurs in two distinct cell types. Plos Pathogens. 7: e1002286. PMID 22007152 DOI: 10.1371/Journal.Ppat.1002286 |
0.743 |
|
2010 |
Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. Journal of Virology. 84: 2395-407. PMID 20015984 DOI: 10.1128/Jvi.01863-09 |
0.725 |
|
2010 |
Schnell G, Joseph S, Spudich S, Price R, Swanstrom R. Where are macrophage-tropic viruses? Journal of the International Aids Society. 13: O3. DOI: 10.1186/1758-2652-13-S3-O3 |
0.71 |
|
2009 |
Harrington PR, Schnell G, Letendre SL, Ritola K, Robertson K, Hall C, Burch CL, Jabara CB, Moore DT, Ellis RJ, Price RW, Swanstrom R. Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. Aids (London, England). 23: 907-15. PMID 19414991 DOI: 10.1097/Qad.0B013E3283299129 |
0.694 |
|
2009 |
Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. Plos Pathogens. 5: e1000395. PMID 19390619 DOI: 10.1371/Journal.Ppat.1000395 |
0.727 |
|
2009 |
Ince WL, Harrington PR, Schnell GL, Patel-Chhabra M, Burch CL, Menezes P, Price RW, Eron JJ, Swanstrom RI. Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization. Journal of Virology. 83: 4068-80. PMID 19211740 DOI: 10.1128/Jvi.02486-08 |
0.787 |
|
2008 |
Schnell G, Ince WL, Swanstrom R. Identification and recovery of minor HIV-1 variants using the heteroduplex tracking assay and biotinylated probes. Nucleic Acids Research. 36: e146. PMID 18948297 DOI: 10.1093/Nar/Gkn713 |
0.75 |
|
Show low-probability matches. |